nach oben

Der Nervenarzt

Erschienen in:

01.01.2006

Früherkennung und Frühintervention der Schizophrenie

verfasst von: Dr. N. Mossaheb, G. Wiesegger, G. P. Amminger, S. Kasper, J. Tauscher

Erschienen in: Der Nervenarzt | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Ergebnisse neuerer Untersuchungen zum Prodromalstadium der Schizophrenie haben wesentliche Erkenntnisse über Möglichkeiten der Früherkennung und Frühintervention erbracht. Die Erkrankung ist mit beträchtlichen sozioökonomischen und sozialen Folgen assoziiert. Die Dauer der unbehandelten Psychose spielt eine wesentliche Rolle im Verlauf der Erkrankung, da eine verzögerte adäquate Behandlung mit einer schlechteren Prognose einhergeht. Bereits im so genannten Prodromalstadium sind soziale, kognitive, affektive und gehirnstrukturelle Veränderung erkennbar. Erste Frühinterventionsstudien deuten auf die Möglichkeit hin, mithilfe indizierter präventiver Intervention, die Übergangsraten bei PatientInnen mit einem erhöhten Risiko für die Entwicklung einer Psychose und bereits manifesten Leistungsdefiziten beträchtlich zu reduzieren. In dieser Übersichtsarbeit werden prodromale Symptome sowie Möglichkeiten der Früherkennung und Frühintervention bei Schizophrenie dargestellt.

Addington J, van Mastrigt S, Addington D (2003) Patterns of premorbid functioning in first-episode psychosis: initial presentation. Schizophr Res 62:23–30CrossRefPubMed

Addington J, Van Mastrigt S, Hutchinson J et al. (2002) Pathways to care: help seeking behaviour in first episode psychosis. Acta Psychiatr Scand 106:358–364CrossRefPubMed

Amminger GP, Edwards J, Brewer WJ et al. (2002) Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 54:223–230CrossRefPubMed

Amminger GP, Pape S, Rock D et al. (1999) Relationship between childhood behavioral disturbance and later schizophrenia in the New York High-Risk Project. Am J Psychiatry 156:525–530PubMed

an der Heiden W, Hafner H (2000) The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 250:292–303

APA (2000) Diagnostic and statistical manual of mental disorders, Text Revision [DSM-IV-TR]. Am Psychiatr Assoc, Washington D.C.

Beckmann H, Jakob H (1991) Prenatal disturbances of nerve cell migration in the entorhinal region: a common vulnerability factor in functional psychoses? J Neural Transm Gen Sect 84:155–164CrossRefPubMed

Birchwood M, McGorry P, Jackson H (1997) Early intervention in schizophrenia. Br J Psychiatry 170:2–5PubMed

Black K, Peters L, Rui Q et al. (2001) Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophr Res 47:215–222CrossRefPubMed

10.

Bogerts B (1999) The neuropathology of schizophrenic diseases: historical aspects and present knowledge. Eur Arch Psychiatry Clin Neurosci 249:IV/2–IV/13

11.

Bonizzato P, Bisoffi G, Amaddeo F et al. (2000) Community-based mental health care: to what extent are service costs associated with clinical, social and service history variables? Psychol Med 30:1205–1215CrossRefPubMed

12.

Byford S, Barber JA, Fiander M et al. (2001) Factors that influence the cost of caring for patients with severe psychotic illness: report from the UK 700 trial. Br J Psychiatry 178:441–447CrossRefPubMed

13.

Cornblatt B, Lencz T, Obuchowski M (2002) The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res 54:177–186CrossRefPubMed

14.

Cornblatt BA, Lencz T, Cornblatt B et al. (2002) The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet 114:956–966CrossRefPubMed

15.

Drake RJ, Haley CJ, Akhtar S et al. (2000) Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 177:511–515CrossRefPubMed

16.

Edwards J, McGorry PD (2002) Implementing early intervention in psychosis. A guide to establishing early psychosis services. Martin Dunitz, London

17.

Emsley R, Myburgh C, Oosthuizen P et al. (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159:1596–1598CrossRefPubMed

18.

Falkai P, Honer W, Alfter D et al. (2002) The temporal lobe in schizophrenia from uni- and multiply affected families. Neurosci Lett 325:25–28CrossRefPubMed

19.

Falloon IR (1992) Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 55:4–15PubMed

20.

Fenton WS, Dickerson F, Boronow J et al. (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158:2071–2074CrossRefPubMed

21.

Fenton WS, Hibbeln J, Knable M (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47:8–21CrossRefPubMed

22.

Garety PA, Rigg A (2001) Early psychosis in the inner city: a survey to inform service planning. Soc Psychiatry Psychiatr Epidemiol 36:537–544CrossRefPubMed

23.

Goldner EM, Hsu L, Waraich P et al. (2002) Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47:833–843PubMed

24.

Gross G, Huber G, Klosterkotter J et al. (1987) BSABS. Bonner Skala für die Beurteilung von Basissymptomen. [Bonn Scale for the Assessment of Basic Symptoms]. Springer, Berlin Heidelberg New York

25.

Hafner H, an der Heiden W (1999) The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 249:14–26

26.

Hafner H, Maurer K, Loffler W et al. (1993) The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80–86PubMed

27.

Harrigan SM, McGorry PD, Krstev H (2003) Does treatment delay in first-episode psychosis really matter? Psychol Med 33:97–110CrossRefPubMed

28.

Ho BC, Alicata D, Ward J et al. (2003) Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry 160:142–148CrossRefPubMed

29.

Huber G (1983) [The concept of substrate-close basic symptoms and its significance for the theory and therapy of schizophrenic diseases]. Nervenarzt 54:23–32PubMed

30.

Kasper S (1999) First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 60:5–9

31.

Kasper S, Hale A, Azorin JM et al. (1999) Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 249:II1–II14PubMed

32.

Kasper S, Rosillon D, Duchesne I (2001) Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 16:179–187

33.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMed

34.

Keshavan MS, Haas G, Miewald J et al. (2003) Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophr Bull 29:757–769PubMed

35.

Klostarkotter J, Schultze-Lutter F, Gross G et al. (1997) Early self-experienced neuropsychological deficits and subsequent schizophrenic diseases: an 8-year average follow-up prospective study. Acta Psychiatr Scand 95:396–404PubMed

36.

Klosterkotter J, Hellmich M, Steinmeyer EM et al. (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164CrossRefPubMed

37.

Knapp M, Chisholm D, Leese M et al. (2002) Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand 105:42–54CrossRefPubMed

38.

Kohn D, Niedersteberg A, Wieneke A et al. (2004) [Early course of illness in first episode schizophrenia with long duration of untreated illness—a comparative study]. Fortschr Neurol Psychiatr 72:88–92CrossRefPubMed

39.

Kraepelin E (1893) Ein kurzes Lehrbuch für Studierende und Ärzte. Abel Verlag, Leipzig

40.

Lachin JL (2000) Statistical considerations in the intent-to-treat principle. Control Clin Trials 21:526CrossRefPubMed

41.

Larsen TK, Joa I (1999) Identifying persons prodromal to first episode schizophrenia: the TOPP-project. Curr Opin Psychiatry 12:207CrossRef

42.

Lawrie SM, Whalley HC, Abukmeil SS et al. (2002) Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. Br J Psychiatry 181:138–143PubMed

43.

Leucht S, Wahlbeck K, Hamann J et al. (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589CrossRefPubMed

44.

Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409–432CrossRefPubMed

45.

Lieberman JA, Perkins D, Belger A et al. (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897CrossRefPubMed

46.

Macdonald EM, Hayes RL, Baglioni AJ Jr. (2000) The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls. Schizophr Res 46:25–30CrossRefPubMed

47.

McGlashan TH, Zipursky RB, Perkins D et al. (2003) The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 61:7–18CrossRefPubMed

48.

McGorry PD, McFarlane C, Patton GC et al. (1995) The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand 92:241–249PubMed

49.

McGorry PD, Yung AR, Phillips LJ et al. (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928CrossRefPubMed

50.

Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425–433

51.

Miller TJ, McGlashan TH, Rosen JL et al. (2002) Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 159:863–865CrossRefPubMed

52.

Morrison AP, Bentall RP, French P et al. (2002) Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry 181(Suppl 43):s78–s84

53.

Morrison AP, French P, Walford L et al. (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291–297CrossRefPubMed

54.

Mrazek P, Haggerty R (1994) Reducing the risk for mental disorders: frontiers for preventive intervention research. National Academy Press, Washington D.C.

55.

Murray CJL, Lopez AD (1996) Global burden of disease. Harvard University Press, Cambridge

56.

Norman RM, Malla AK (2001) Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 31:381–400PubMed

57.

Pantelis C, Velakoulis D, McGorry PD et al. (2003) Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281–288CrossRefPubMed

58.

Pantelis C, Yucel M, Wood SJ et al. (2003) Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust N Z J Psychiatry 37:399–406CrossRefPubMed

59.

Peet M, Brind J, Ramchand CN et al. (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49:243–251CrossRefPubMed

60.

Phillips LJ, Velakoulis D, Pantelis C et al. (2002) Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr Res 58:145–158CrossRefPubMed

61.

Rabinowitz J, De Smedt G, Harvey PD et al. (2002) Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. Am J Psychiatry 159:2021–2026CrossRefPubMed

62.

Reichenberg A, Weiser M, Rabinowitz J et al. (2002) A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry 159:2027–2035CrossRefPubMed

63.

Ruhrmann S, Schultze-Lutter F, Klostarkotter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36:S162–S167CrossRefPubMed

64.

Smith GN, Lang DJ, Kopala LC et al. (2003) Developmental abnormalities of the hippocampus in first-episode schizophrenia. Biol Psychiatry 53:555–561CrossRefPubMed

65.

Tkachev D, Mimmack ML, Ryan MM et al. (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798–805CrossRefPubMed

66.

Tsuang MT, Stone WS, Tarbox SI et al. (2002) An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophr Res 54:169–175CrossRefPubMed

67.

Velakoulis D, Pantelis C, McGorry PD et al. (1999) Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Arch Gen Psychiatry 56:133–141CrossRefPubMed

68.

Verdoux H, Liraud F, Gonzales B et al. (2001) Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr Scand 103:347–354CrossRefPubMed

69.

Wakade CG, Mahadik SP, Waller JL et al. (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69:72–79CrossRefPubMed

70.

Weinberger DR (1988) Premorbid neuropathology in schizophrenia. Lancet 2:445CrossRefPubMed

71.

WHO (1993) International Statistical Classification of Diseases and Related Health Problems, tenth revision. WHO, Geneva

72.

Woods SW, Breier A, Zipursky RB et al. (2003) Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 54:453–464CrossRefPubMed

73.

Wright IC, Rabe-Hesketh S, Woodruff PW et al. (2000) Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157:16–25PubMed

74.

Yung A (2000) The Comprehensive Assessment of At-Risk Mental States (CAARMS). University of Australia, Melbourne

75.

Yung AR, Phillips LJ, McGorry PD et al. (1998) Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 172:14–20PubMed

Titel: Früherkennung und Frühintervention der Schizophrenie
verfasst von: Dr. N. Mossaheb
G. Wiesegger
G. P. Amminger
S. Kasper
J. Tauscher
Publikationsdatum: 01.01.2006
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 1/2006
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-005-1925-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Früherkennung und Frühintervention der Schizophrenie

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Wie wirbt man erfolgreich um Mitarbeiter?

Mitteilungen Young Psychiatrists Newsletter 1/2006

Polyzystische lipomembranöse Osteodysplasie mit sklerosierender Leukenzephalopathie

Sexuelle Funktionsstörungen aus nervenärztlicher Perspektive

Zur Frühgeschichte von „Ecstasy“

Langfristige Auswirkungen traumatischer Ereignisse auf somatische und psychische Beschwerden

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko